7.
Safety summary
| Variable | n (%) | |||
| Docetaxel/anthracycline combo (N=1,421) | Docetaxel/anthracycline sequential (N=447) | Docetaxel/other
(N=705) |
Other
(N=447) |
|
| TEAE, treatment emergent adverse event; CTCAE, common terminology criteria for adverse events; *, no grade 5 TEAEs reported. | ||||
| Patients with ≥1 TEAE | 1,093 (76.9) | 293 (65.5) | 525 (74.5) | 277 (62.0) |
| Patients with ≥1 serious TEAE | 138 (9.7) | 25 (5.6) | 55 (7.8) | 43 (9.6) |
| Patients with ≥1 hematological TEAE | 937 (65.9) | 164 (36.7) | 390 (55.3) | 225 (50.3) |
| Patients with ≥1 cardiovascular TEAE | 2 (0.1) | 5 (1.1) | 3 (0.4) | 1 (0.2) |
| Patients with ≥1 TEAE by CTCAE grade* | ||||
| Grade 1 | 860 (60.5) | 250 (55.9) | 386 (54.8) | 217 (48.5) |
| Grade 2 | 844 (59.4) | 312 (69.8) | 359 (50.9) | 223 (49.9) |
| Grade 3 | 418 (29.4) | 114 (25.5) | 167 (23.7) | 94 (21.0) |
| Grade 4 | 158 (11.1) | 35 (7.8) | 82 (11.6) | 34 (7.6) |
| Missing | 108 (7.6) | 2 (0.4) | 31 (4.4) | 21 (4.7) |